Novel Anticoagulant Use for Venous Thromboembolism: A 2013 Update
- 465 Downloads
Many pharmacologic options are available for prevention and treatment of venous thromboembolism (VTE). The anticoagulant selected may vary according the individual patient situation such as the acute versus chronic setting, renal function and indication for either VTE prevention or treatment. Established methods of pharmacologic prophylaxis agents include heparinoids, injectable anti-Xa inhibition and vitamin K antagonists (VKA). The novel anticoagulants have recently been incorporated into orthopedic surgery prophylaxis pathways and can be used for VTE treatment. Chronic VTE management, however, has largely been managed with the use VKA. The advantages of VKA include low cost, familiarity with use, and established protocols to manage catastrophic bleeding. VKA use, however, poses hurdles including the fact that correct dosing can be empiric, the existence of multiple potential medication and dietary interactions, and the possiblity for complications when anticoagulation levels are not well monitored. In contrast, the novel anticoagulants offer ease of dosing, reliable pharmacokinetics and low risk of interactions with other medications or diet. Potential hazards of the novel anticoagulants include high costs, questionable therapeutic benefit in those with poor adherence, a reliance on renal clearance, lack of reliable reversibility in the event of catastrophic bleeding, as well as incomplete familiarity with use by the general practitioner. Although clinical trials demonstrate promise of greater applicability of use of these novel agents, hospital systems will need to simultaneously create a plan for appropriate management of the use of these agents, an anticoagulation stewardship program. As guidelines are adopted to prevent and manage VTE, an appreciation for this new level of complexity is essential.
KeywordsAnticoagulant Apixaban Bleeding Dabigatran Deep vein thrombosis (DVT) Factor Xa Fondaparinux Heparin Low-molecular-weight heparin Novel anticoagulant Prophylaxis Pulmonary embolism (PE) Rivaroxaban Stewardship Total hip arthroplasty (THA) Total hip arthroplasty (TKA) Venous thromboembolism Vitamin K antagonist (VKA) Warfarin
Dr. Alejandro Perez reported no conflicts of interest relevant to this article.
Dr. Geno Merli received research grants from Portola Pharmaceutical Co, BMS, Bayer, and Sanofi-Aventis.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as:• Of importance •• Of major importance
- 1.••Yusuf HR, Tsai J, Atrash HK, et al. Venous thromboembolism in Adult Hospitalizations – United States, 2007-2009. MMWR. 2012;61:401–4. Centers for Disease Control and Prevention (CDC) analyzed 2007-2009 data from the National Hospital Discharge Survey (NHDS). A yearly average of 547,596 hospitalizations with VTE occurred among those aged ≥18 years in the US. A yearly average of 348,558 hospitalizations had DVT and 277,549 had PE; 78,511 hospitalizations had PE and DVT.Google Scholar
- 5.Schofield FW. Damaged sweet clover: The cause of a new disease in cattle simulating hermorrhagic septicemia and blackleg. J Am Vet Med Assoc. 1924;64:553.Google Scholar
- 7.•Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141:e195S–226S. This article provides a comprehensive update of recommendations for VTE prevention in nonsurgical patients.Google Scholar
- 8.US Department of Health and Human Services. Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism 2008. Available at: http://www.surgeongeneral.gov/library/calls/deepvein/ Accessed October 2012.
- 9.Moore TJ, Bennet CL Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: Empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012 [Epub ahead of print/ Accessed October 2012].Google Scholar
- 20.Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141:e278S–e325S. This article provides a comprehensive update of recommendations for VTE prevention in orthopedic surgery patients.Google Scholar
- 27.The RE-MOBILIZE. Writing Committee: Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1–9.Google Scholar
- 30.Schulman S, Ericsson H, Goldhaber SZ, et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. J Thromb Haemost. 2011;9:731. Abstract O-TH-033.Google Scholar
- 31.••Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172:397–402. This is a systematic review of seven trials using dabigatran for various indications including stroke prophylaxis in atrial fibrillation, acute coronary syndrome (ACS), acute VTE, and VTE prevention. Dabigatran was associated with a higher risk of myocardial infarction (MI) or ACS than comparison group (dabigatran, [1.19 %] vs. control, [0.79 %]; OR 1.33; P = .03).PubMedCrossRefGoogle Scholar
- 32.Schulman S, Baanstra D, Eriksson H, et al. Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism. J Thromb Haemost. 2011;9:22. Abstract O-MO-037.Google Scholar